Chemiluminescent Immunoassay (CLIA)
May aid as a marker for prostate cancer. Do not use as a screening procedure as PSA has been observed in patient's with benign prostatic hypertrophy. Diagnostic PSA (DPSA) should be utilized for patients with a diagnosis of prostate cancer.
MALE: Age 0 - 49 yrs: 0 - 2.5 ng/mL, Age 50 - 59 yrs: 0 - 3.5 ng/mL, Age 60 - 69 yrs: 0 - 4.5 ng/mL, Age 70 - 150 yrs: 0 - 6.5 ng/mL. FEMALE: Age 0 - 150 yrs: 0 - 0.1 ng/mL.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
Collect specimen in an SST or red top tube. Centrifuge, aliquot serum into plastic vial. Refrigerate up to 8 hours or freeze for longer storage. Transport to MLabs as a frozen aliquot. Please indicate whether test is being orderd for Screening (PSA) or Diagnostic (DPSA) purposes.
Prostate Specific Antigen is a more sensitive marker of prostatic adenocarcinoma than Prostatic Acid Phosphatase.